511 related articles for article (PubMed ID: 18445080)
1. Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting.
O'Leary MP; Wei JT; Roehrborn CG; Miner M;
BJU Int; 2008 Jun; 101(12):1531-5. PubMed ID: 18445080
[TBL] [Abstract][Full Text] [Related]
2. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N
BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
[TBL] [Abstract][Full Text] [Related]
3. Profile and management of patients treated for the first time for lower urinary tract symptoms/benign prostatic hyperplasia in four European countries.
Fourcade RO; Théret N; Taïeb C;
BJU Int; 2008 May; 101(9):1111-8. PubMed ID: 18279447
[TBL] [Abstract][Full Text] [Related]
4. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry.
Rosen RC; Wei JT; Althof SE; Seftel AD; Miner M; Perelman MA;
Urology; 2009 Mar; 73(3):562-6. PubMed ID: 19167031
[TBL] [Abstract][Full Text] [Related]
5. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
[TBL] [Abstract][Full Text] [Related]
6. The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics.
Roehrborn CG; Nuckolls JG; Wei JT; Steers W;
BJU Int; 2007 Oct; 100(4):813-9. PubMed ID: 17822462
[TBL] [Abstract][Full Text] [Related]
7. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.
Barkin J; Roehrborn CG; Siami P; Haillot O; Morrill B; Black L; Montorsi F;
BJU Int; 2009 Apr; 103(7):919-26. PubMed ID: 19239460
[TBL] [Abstract][Full Text] [Related]
8. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.
Tsukamoto T; Masumori N; Rahman M; Crane MM
Int J Urol; 2007 Apr; 14(4):321-4; discussion 325. PubMed ID: 17470162
[TBL] [Abstract][Full Text] [Related]
9. Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH.
Nickel JC; Elhilali M; Vallancien G;
BJU Int; 2005 Mar; 95(4):571-4. PubMed ID: 15705082
[TBL] [Abstract][Full Text] [Related]
10. Ejaculatory dysfunction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Rosen RC; Fitzpatrick JM;
BJU Int; 2009 Oct; 104(7):974-83. PubMed ID: 19426189
[TBL] [Abstract][Full Text] [Related]
11. [Quality of life assessment of the male with benign prostate hypertrophy].
Nekić VC; Tiljak H; Petricek G; Soldo D; Nekić G; Buljan N
Acta Med Croatica; 2007 Feb; 61(1):49-55. PubMed ID: 17593641
[TBL] [Abstract][Full Text] [Related]
12. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
Suzuki H; Yano M; Awa Y; Nakatsu H; Egoshi K; Mikami K; Ota S; Okano T; Hamano S; Ohki T; Furuya Y; Ichikawa T
Int J Urol; 2006 Sep; 13(9):1202-6. PubMed ID: 16984553
[TBL] [Abstract][Full Text] [Related]
14. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
15. Association between erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia in Nigerian men.
Ikuerowo SO; Akindiji YO; Akinoso OA; Akinlusi FM; Esho JO
Urol Int; 2008; 80(3):296-9. PubMed ID: 18480635
[TBL] [Abstract][Full Text] [Related]
16. Correlation of prostate volume with international prostate symptom score and quality of life in men with benign prostatic hyperplasia.
Agrawal CS; Chalise PR; Bhandari BB
Nepal Med Coll J; 2008 Jun; 10(2):104-7. PubMed ID: 18828432
[TBL] [Abstract][Full Text] [Related]
17. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
Emberton M; Elhilali M; Matzkin H; Harving N; van Moorselaar J; Hartung R; Alcaraz A; Vallancien G;
Urology; 2005 Aug; 66(2):316-22. PubMed ID: 16098361
[TBL] [Abstract][Full Text] [Related]
18. Change in urinary symptoms and quality of life in men with benign prostatic hyperplasia after transurethral resection of prostate.
Chalise PR; Agrawal CS
Nepal Med Coll J; 2007 Dec; 9(4):255-8. PubMed ID: 18298015
[TBL] [Abstract][Full Text] [Related]
19. Can benign prostatic hyperplasia be identified in the primary care setting using only simple tests? Results of the Diagnosis IMprovement in PrimAry Care Trial.
Carballido J; Fourcade R; Pagliarulo A; Brenes F; Boye A; Sessa A; Gilson M; Castro R
Int J Clin Pract; 2011 Sep; 65(9):989-96. PubMed ID: 21733048
[TBL] [Abstract][Full Text] [Related]
20. Relationship between lower urinary tract symptoms frequency assessed by the IPSS and bothersomeness (SPI) among men older than 50 years old.
Perrin P; Marionneau N; Cucherat M; Taieb C
Eur Urol; 2005 Oct; 48(4):601-7. PubMed ID: 16055260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
